Journal of Medical Economics
Volume 24, 2021 - Issue 1
Hematology
Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States
Claire L. Simonsa Pharmerit – An OPEN Health Company, York, UKCorrespondence[email protected]
https://orcid.org/0000-0003-0822-7261
https://orcid.org/0000-0003-0822-7261, Daniel Maloneb L. S. Skaggs Research Institute, The University of Utah College of Pharmacy, Salt Lake City, UT, USAhttps://orcid.org/0000-0002-5006-9394
https://orcid.org/0000-0002-5006-9394, Michael Wangc Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAhttps://orcid.org/0000-0001-9748-5486
https://orcid.org/0000-0001-9748-5486, Gregory A. Maglinted Kite, a Gilead Company, Santa Monica, CA, USAhttps://orcid.org/0000-0001-7130-2557
https://orcid.org/0000-0001-7130-2557, Tim Inocencioe Pharmerit – An OPEN Health Company, Bethesda, MD, USAhttps://orcid.org/0000-0003-3394-4078
https://orcid.org/0000-0003-3394-4078, Sally W. Wadef Wade Outcomes Research and Consulting, Salt Lake City, UT, USAhttps://orcid.org/0000-0003-4726-7995
https://orcid.org/0000-0003-4726-7995, Craig Bennisona Pharmerit – An OPEN Health Company, York, UKhttps://orcid.org/0000-0001-8658-5510
https://orcid.org/0000-0001-8658-5510 & Bijal Shahg Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USAhttps://orcid.org/0000-0003-4328-6021
https://orcid.org/0000-0003-4328-6021 show all